Biosimilar

Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.

Biosimilar medications — drugs developed to be very similar, but not identical, to an FDA-approved biologic — were intended to play a vital role in increasing affordable options for patients struggling with a range of chronic conditions.

The American College of Rheumatology has applauded an FDA proposal to streamline the approval of interchangeable biosimilars, removing requirements for switching studies to determine their interchangeability with reference products.

Undoubtedly, cost can be a barrier to optimal anti-VEGF treatment in the United States and around the world.

It has been nearly 3 years since the first ranibizumab biosimilar was approved for use in the U.S.

Most of us are familiar with the different classes of eye drops.

Subcutaneous TNF inhibitors and their biosimilars are discontinued due to inefficacy and adverse events at similar rates in patients with rheumatic diseases, according to data from Spain published in The Journal of Rheumatology.

Welcome to the first-ever Healio Rheum for Debate, in which we ask experts to take opposing sides and match wits on major topics in the field of rheumatology.

In patients with rheumatoid arthritis who have an inadequate response to methotrexate, a treatment sequence beginning with a biosimilar appeared cost-effective compared with leflunomide, according to data published in JAMA Network Open.